Shkodina A. D.

COGNITIVE AND MOTOR IMPAIRMENTS IN DIFFERENT MOTOR SUBTYPES OF PARKINSON DISEASE AND PATIENTS’ QUALITY OF LIFE

---

Show/Download

About the author:

Shkodina A. D.

Heading:

CLINICAL AND EXPERIMENTAL MEDICINE

Type of article:

Scientific article

Annotation:

Numerous motor and non-motor symptoms characterize Parkinson's disease. Modern research increasingly focuses on their relationship and role in patients' quality of life. Our study aimed to evaluate cognitive and motor impairment in different motor subtypes of PD and analyze their relationship with quality of life. The study included 64 patients with Parkinson's disease, divided according to motor subtype: group 1 - patients with PD subtype with a predominance of postural instability and gait disorders; group 2 - patients with PD subtype with a predominance of tremor or intermediate subtype. The patients were examined using the Unified Parkinson's Disease Rating Scale, the Hoehn and Yahr scale, the Montreal Cognitive Assessment Scale, and the Parkinson's Disease Quality of Life Scale. It was found that group 1 had a statistically significant higher score on the "mobility" (p=0.004) and "emotional well-being" (p=0.013) scales, indicating a greater severity of motor function impairment and psychoemotional disorders in these patients. At the same time, the score on the "stigmatization" scale was found to be higher in group 2 (p=0.049). There were no differences in the scales of "daily activity", "social support", "cognition", "communication" and "body discomfort". The total score on the PDQ-39 scale was higher in group 1 compared to group 2 (p=0.042), indicating a worse quality of life. We found a worse quality of life in patients with PIGD subtype of PD, in particular in the domains of mobility and "emotional well-being", while patients with non-PIGD subtype were characterized by a more acute perception of disease stigma, in the absence of differences in the severity of clinical symptoms and cognitive impairment.

Tags:

Bibliography:

1. Aborode AT, Pustake M, Awuah WA, Alwerdani M, Shah P, Yarlagadda R, et al. Targeting Oxidative Stress Mechanisms to Treat Alzheimer’s and Parkinson’s Disease: A Critical Review. Oxid Med Cell Longev. 2022;2022:1–9. DOI: https://doi.org/10.1155/2022/7934442.
2. Shkodina AD, Tan SC, Hasan MM, Abdelgawad M, Chopra H, Bilal M, et al. Roles of clock genes in the pathogenesis of Parkinson’s disease. Ageing Res Rev. 2022;74:101554. DOI: https://doi.org/10.1016/j.arr.2021.101554.
3. Hoseinipalangi Z, Kan FP, Hosseinifard H, Doustmehraban M, Masoumi M, Rafiei S, et al. Systematic review and meta-analysis of the quality-of-life of patients with Parkinson’s disease. East Mediterr Heal J. 2023;29:63–70. DOI: https://doi.org/10.26719/emhj.23.013.
4. Zhao N, Yang Y, Zhang L, Zhang Q, Balbuena L, Ungvari GS, et al. Quality of life in Parkinson’s disease: A systematic review and metaanalysis of comparative studies. CNS Neurosci Ther. 2021;27:270–9. DOI: https://doi.org/10.1111/cns.13549.
5. Alvarado-Bolaños A, Cervantes-Arriaga A, Zuazua-Vidal L, Esquivel-Zapata Ó, Alcocer-Salas Á, Rodríguez-Violante M. Determinants and impact of alexithymia on quality of life in Parkinson’s disease. Neurol (English Ed). 2023;38:334–41. DOI: https://doi.org/10.1016/j. nrleng.2020. 10.015.
6. Skrypnikov AM, Zhyvotovska LV, Herasymenko LO, Boiko DI, Bodnar LA. Alexithymia in healthy people and its role in development of different disorders. Med Ecol Probl. 2019;23:30–3. DOI: https://doi.org/10.31718/ mep.2019.23.1-2.07.
7. Balestrino R, Martinez-Martin P. Neuropsychiatric symptoms, behavioural disorders, and quality of life in Parkinson’s disease. J Neurol Sci. 2017;373:173–8. DOI: https://doi.org/10.1016/j.jns.2016.12.060.
8. Ren J, Hua P, Li Y, Pan C, Yan L, Yu C, et al. Comparison of Three Motor Subtype Classifications in de novo Parkinson’s Disease Patients. Front Neurol. 2020;11. DOI: https://doi.org/10.3389/fneur.2020.601225.
9. Wu D-D, Su W, He J, Li S-H, Li K, Chen H-B. Nonmotor symptoms and quality of life in Parkinson’s disease with different motor subtypes. Z Gerontol Geriatr. 2022;55:496–501. DOI: https://doi.org/10.1007/s00391-021-01950-3.
10. Wu Y, Guo X-Y, Wei Q-Q, Ou R-W, Song W, Cao B, et al. Non-motor symptoms and quality of life in tremor dominant vs postural instability gait disorder Parkinson’s disease patients. Acta Neurol Scand. 2016;133:330–7. DOI: https://doi.org/10.1111/ane.12461.
11. Stebbins GT, Goetz CG, Burn DJ, Jankovic J, Khoo TK, Tilley BC. How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson’s disease rating scale: Comparison with the unified Parkinson’s disease rating scale. Mov Disord. 2013;28:668–70. DOI: https://doi.org/10.1002/mds.25383.
12. Schönenberg A, Prell T. Measuring quality of life with the Parkinson’s Disease Questionnaire-39 in people with cognitive impairment. PLoS One. 2022;17:e0266140. DOI: https://doi.org/10.1371/journal.pone.0266140.
13. Hariz G-M, Forsgren L. Activities of daily living and quality of life in persons with newly diagnosed Parkinson’s disease according to subtype of disease, and in comparison to healthy controls. Acta Neurol Scand. 2011;123:20–7. DOI: https://doi.org/10.1111/j.1600- 0404.2010.01344.x.
14. Huang X, Ng SY-E, Chia NS-Y, Setiawan F, Tay K-Y, Au W-L, et al. Non-motor symptoms in early Parkinson’s disease with different motor subtypes and their associations with quality of life. Eur J Neurol. 2019;26:400–6. DOI: https://doi.org/10.1111/ene.13803.
15. Boiko DI, Skrypnikov AM, Shkodina AD, Hasan MM, Ashraf GM, Rahman MH. Circadian rhythm disorder and anxiety as mental health complications in post-COVID-19. Environ Sci Pollut Res. 2022;29:28062–9. DOI: https://doi.org/10.1007/s11356-021-18384-4.
16. Kay KR, Uc EY. Progress in brain research. Elsevier; 2022. Chapter 5, Real-life consequences of cognitive dysfunction in Parkinson’s disease; p. 113–36. DOI: https://doi.org/10.1016/bs.pbr.2022.01.005.
17. Candel-Parra E, Córcoles-Jiménez MP, Delicado-Useros V, Ruiz-Grao MC, Hernández-Martínez A, Molina-Alarcón M. Predictive Model of Quality of Life in Patients with Parkinson’s Disease. Int J Environ Res Public Health. 2022;19:672. DOI: https://doi.org/10.3390/ ijerph19020672.
18. Hermanowicz N, Jones SA, Hauser RA. Impact of non-motor symptoms in Parkinson’s disease: a PMDAlliance survey. Neuropsychiatr Dis Treat. 2019;15:2205–12. DOI: https://doi.org/10.2147/NDT.S213917.
19. Reginold W, Duff-Canning S, Meaney C, Armstrong MJ, Fox S, Rothberg B, et al. Impact of Mild Cognitive Impairment on Health-Related Quality of Life in Parkinson’s Disease. Dement Geriatr Cogn Disord. 2013;36:67–75. DOI: https://doi.org/10.1159/000350032.
20. Shkodina AD, Tarianyk KA, Boiko DI, Zehravi M, Akter S, Md. Ashraf G, et al. Cognitive and affective disturbances in patients with Parkinson’s disease: Perspectives for classifying of motor/neuropsychiatric subtypes. Neurosci Lett. 2022;781:136675. DOI: https://doi. org/10.1016/j.neulet.2022.136675.
21. Minibajeva O, Zeltiņa E, Karelis G, Kurjāne N, Ķēniņa V. Clinical Symptoms Influencing Parkinson’s Patients’ Quality of Life in Latvia: A Single-Center Cohort Study. Medicina (B Aires). 2023;59:935. DOI: https://doi.org/10.3390/medicina59050935.
22. Fereshtehnejad S-M. Strategies to maintain quality of life among people with Parkinson’s disease: what works? Neurodegener Dis Manag. 2016;6:399–415. DOI: https://doi.org/10.2217/nmt-2016-0020.

Publication of the article:

«Bulletin of problems biology and medicine», 2024 Issue 1, 172, 247-256 pages, index UDC 616.858-071-085

DOI:

10.29254/2077-4214-2024-1-172-247-256